Are we in trouble?

Quote

Anonymous

Guest
Are we in trouble as a compnay ? I think every division has some MAJOR changes coming. From another Access layoff, BVP issues, BBS and EP buyout rumors, and Davol lawsuits with more to come...... I think it may be time to cash out the ESOP and move on.. This place is a scary and unpredictable place to be for all of us.
 






You are insightful. I cashed out at $108, especially since our 1 year target price is $105. 2014 is going to be rough with Obamacare and the stockholders will still be looking for growth. The quickest way to help the bottom line is to reduce labor costs.
 
















































Lawyers, plaintiffs and slings will be with us for a long while:

.CR Bard Case Over Vaginal Mesh Defects Declared Mistrial
By Jef Feeley & Phil Milford - Jul 10, 2013 1:52 PM CT ..Facebook Share Tweet LinkedIn Google +1 0 Comments
Print QUEUEQ..CR Bard Inc. (BCR) may have to face another jury in a product-liability case over vaginal-mesh devices after a federal judge today declared a mistrial because of a witness’s testimony.

U.S. District Judge Joseph Goodwin in Charleston, West Virginia, stopped the trial in its second day after Lennox Hoyte, a gynecological expert from Tampa, Florida, strayed into testimony about the devices’ marketing. Goodwin had ruled earlier that the plaintiffs couldn’t mention Bard had withdrawn the productS last year.

“I don’t think it’s a bell that can be unrung,” Goodwin said. “It would be very difficult for the jury to disregard.”

Bard, based in Murray Hill, New Jersey, faces at least 3,600 claims over its Avaulta Plus vaginal mesh, which plaintiffs allege can cause internal damage.

Implant makers including Johnson & Johnson (JNJ), Endo Health Solutions Inc. (ENDP) and Boston Scientific Corp. (BSX) face similar claims that their products degrade and shrink over time.

“We’re disappointed the plaintiff’s witness blurted what he did and forced us to ask for a mistrial,” said Lori Cohen, a lawyer for Bard.

The cases are In re C.R. Bard Inc. Pelvic Repair System Products Liability Litigation, 2:10-md-02187, and Cisson v. C.R. Bard Inc., 2:11-cv-00195, U.S. District Court, Southern District of West Virginia (Charleston).

To contact the reporters on this story: Jef Feeley in Charleston, West Virginia, at jfeeley@bloomberg.net; Phil Milford in Wilmington at pmilford@bloomberg.net
 


















Anonymous said:
Take a look at stock price you assclown. This company is rocking and rolling.
Click to expand...

Stock hasn't done shit in over a year. Steady and waiting for the next earning statement to come out so we can get crushed. Bard as a company is lucky to be flat in the domestic marketplace. You need to fire your broker!

Go work on your spreadsheets, I'm sure you have some sort of report due. Ya douche
 






Anonymous said:
Stock hasn't done shit in over a year. Steady and waiting for the next earning statement to come out so we can get crushed. Bard as a company is lucky to be flat in the domestic marketplace. You need to fire your broker!

Go work on your spreadsheets, I'm sure you have some sort of report due. Ya douche
Click to expand...

No BS. THE FDA want real data compared to a control group for Lutonix. We are screwed.
 
























Top Bottom
Back
Quote